Zanolimumab: Difference between revisions
Content deleted Content added
m Identifier not assigned: use =none (CAS RN, ChemSpider, ATC) (via AWB script) |
m molar mass: correct unit (should be g/mol). No need to link SI units. rm depr parameter imagename (via AWB script) |
||
| Line 41: | Line 41: | ||
<!-- Chemical data --> |
<!-- Chemical data --> |
||
| chemical_formula = |
| chemical_formula = |
||
| molecular_weight = 147 |
| molecular_weight = 147 kg/mol |
||
}} |
}} |
||
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4]</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It is being developed for the treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>http://www.tenxbiopharma.com/development.shtml</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> The drug is currently undergoing Phase II trials.<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|accessdate=6 November 2011}}</ref> |
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4]</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]]. It is being developed for the treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>http://www.tenxbiopharma.com/development.shtml</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> The drug is currently undergoing Phase II trials.<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|accessdate=6 November 2011}}</ref> |
||
Revision as of 21:04, 3 April 2016
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | 147 kg/mol |
  (what is this?) (verify) | |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] The drug is currently undergoing Phase II trials.[5]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ http://www.tenxbiopharma.com/development.shtml
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- ^ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |